Ranibizumab
(Anti-human VEGFA mAb, human IgG1-Kappa; RG6321)
Catalog No.: PC-Ab1063Not For Human Use, Lab Use Only.
Ranibizumab (Lucentis, RG-6321) is a specific affinity-matured, recombinant, humanized, anti-VEGF antigen-binding antibody fragment (Fab) that binds and neutralizes all the biologically active forms of VEGF-A, an important mediator in the development of choroidal neovascularisation. Ranibizumab was approved by the Food and Drug Administration (FDA) for the treatment of neovascular AMD..
Ranibizumab (Lucentis, RG-6321) is a specific affinity-matured, recombinant, humanized, anti-VEGF antigen-binding antibody fragment (Fab) that binds and neutralizes all the biologically active forms of VEGF-A, an important mediator in the development of choroidal neovascularisation. Ranibizumab was approved by the Food and Drug Administration (FDA) for the treatment of neovascular AMD.
Physicochemical Properties
M.Wt
Formula
Human IgG1-Kappa
Appearance
Solid
CAS No.
Storage
Solide Powder
-20 °C 12 Months; 4°C 6 Months
In Solvent
-80 °C 6 Months; -20°C 6 Months
Shipping
Solubility
PBS, pH 7.0
Contains no stabilizers or preservatives
